Inhibrx (INBX) News Today $15.08 +0.53 (+3.64%) (As of 01:28 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Short Interest in Inhibrx, Inc. (NASDAQ:INBX) Expands By 5.8%December 18 at 2:26 AM | americanbankingnews.comAnalyzing Kyverna Therapeutics (NASDAQ:KYTX) & Inhibrx (NASDAQ:INBX)December 18 at 1:32 AM | americanbankingnews.comInhibrx, Inc. (NASDAQ:INBX) Short Interest Up 5.8% in NovemberInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 1,090,000 shares, a growth of 5.8% from the November 15th total of 1,030,000 shares. Based on an average daily volume of 84,700 shares, the days-to-cover ratio is presently 12.9 days. Currently, 11.0% of the company's stock are sold short.December 16 at 2:39 AM | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Director Jon Faiz Kayyem Buys 69,686 SharesNovember 23, 2024 | insidertrades.comJon Faiz Kayyem Purchases 69,686 Shares of Inhibrx, Inc. (NASDAQ:INBX) StockInhibrx, Inc. (NASDAQ:INBX - Get Free Report) Director Jon Faiz Kayyem bought 69,686 shares of Inhibrx stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average price of $14.23 per share, with a total value of $991,631.78. Following the purchase, the director now owns 51,093 shares in the company, valued at approximately $727,053.39. This represents a -374.80 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.November 22, 2024 | marketbeat.comInhibrx Biosciences, Inc. (INBX)November 22, 2024 | finance.yahoo.comThe recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the sharesNovember 21, 2024 | uk.finance.yahoo.comJMP Securities Sticks to Their Hold Rating for Inhibrx Biosciences Inc (INBX)November 18, 2024 | markets.businessinsider.comInhibrx, Inc. (NASDAQ:INBX) Short Interest Up 9.0% in OctoberInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 976,700 shares, a growth of 9.0% from the October 15th total of 895,700 shares. Currently, 9.7% of the company's shares are short sold. Based on an average daily volume of 89,700 shares, the short-interest ratio is currently 10.9 days.November 17, 2024 | marketbeat.comInhibrx Biosciences, Inc.: Inhibrx Biosciences Reports Third Quarter 2024 Financial ResultsNovember 15, 2024 | finanznachrichten.deStocks Close Lower on Hawkish PowellNovember 14, 2024 | msn.comInhibrx Biosciences Inc (INBX)November 14, 2024 | investing.comInhibrx Biosciences Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | prnewswire.comInhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique PlatformNovember 5, 2024 | seekingalpha.comInhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and InnovationNovember 4, 2024 | prnewswire.comInhibrx Biosciences (NASDAQ:INBX) Stock Quotes, Forecast and News SummaryOctober 18, 2024 | benzinga.comInhibrx, Inc. (NASDAQ:INBX) Short Interest UpdateInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the target of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 742,500 shares, an increase of 9.6% from the September 15th total of 677,700 shares. Based on an average trading volume of 106,900 shares, the short-interest ratio is presently 6.9 days. Approximately 7.4% of the shares of the company are short sold.October 16, 2024 | marketbeat.comInhibrx CEO buys shares worth over $629kSeptember 19, 2024 | investing.comInhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Purchases 13,037 SharesSeptember 17, 2024 | insidertrades.comDirector Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)September 13, 2024 | finance.yahoo.comInhibrx, Inc. (NASDAQ:INBX) CEO Purchases $144,495.00 in StockSeptember 11, 2024 | insidertrades.comInhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Purchases 9,500 SharesInhibrx, Inc. (NASDAQ:INBX - Get Free Report) CEO Mark Lappe acquired 9,500 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were bought at an average price of $15.21 per share, for a total transaction of $144,495.00. Following the transaction, the chief executive officer now owns 657,048 shares of the company's stock, valued at $9,993,700.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.September 10, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Acquires 10,000 SharesSeptember 4, 2024 | insidertrades.comInsider Buying: Inhibrx, Inc. (NASDAQ:INBX) CEO Buys 10,000 Shares of StockInhibrx, Inc. (NASDAQ:INBX - Get Free Report) CEO Mark Lappe acquired 10,000 shares of the company's stock in a transaction on Thursday, August 29th. The stock was acquired at an average cost of $14.03 per share, with a total value of $140,300.00. Following the completion of the purchase, the chief executive officer now directly owns 135,000 shares in the company, valued at $1,894,050. The purchase was disclosed in a filing with the SEC, which is available at this link.September 3, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Sees Large Growth in Short InterestInhibrx, Inc. (NASDAQ:INBX - Get Free Report) saw a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 752,900 shares, an increase of 6.0% from the July 31st total of 710,400 shares. Approximately 7.3% of the company's shares are short sold. Based on an average trading volume of 203,400 shares, the short-interest ratio is currently 3.7 days.September 2, 2024 | marketbeat.comInhibrx gains after insider purchases from CEOAugust 23, 2024 | msn.comINBX Stock Earnings: Inhibrx Beats EPS for Q1 2024August 22, 2024 | investorplace.comINBX Inhibrx Biosciences, Inc.August 17, 2024 | seekingalpha.comInhibrx (NASDAQ:INBX) Posts Quarterly Earnings Results, Beats Estimates By $129.08 EPSInhibrx (NASDAQ:INBX - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $125.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.60) by $129.08. The business had revenue of $0.10 million for the quarter.August 14, 2024 | marketbeat.comInhibrx Biosciences, Inc.: Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 14, 2024 | finanznachrichten.deJMP Securities Remains a Hold on Inhibrx Biosciences Inc (INBX)August 14, 2024 | markets.businessinsider.comInhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 13, 2024 | prnewswire.comJMP Securities Initiates Coverage of Inhibrx Biosciences (INBX) with Market Perform RecommendationJuly 24, 2024 | msn.comJMP Securities Begins Coverage on Inhibrx (NASDAQ:INBX)JMP Securities initiated coverage on shares of Inhibrx in a report on Tuesday. They set a "market perform" rating for the company.July 23, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Shares Sold by Russell Investments Group Ltd.Russell Investments Group Ltd. trimmed its position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 56.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 190,389 shares of the compaJuly 22, 2024 | marketbeat.comInhibrx (NASDAQ:INBX) Shares Down 2.4% Inhibrx (NASDAQ:INBX) Trading Down 2.4%June 12, 2024 | marketbeat.comInhibrx (NASDAQ:INBX) Shares Gap Up on Insider Buying ActivityInhibrx (NASDAQ:INBX) Shares Gap Up Following Insider Buying ActivityJune 10, 2024 | marketbeat.comPlatinum Investment Management Ltd. Sells 61,273 Shares of Inhibrx, Inc. (NASDAQ:INBX)Platinum Investment Management Ltd. cut its position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 26.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,763 shares of the company's stockJune 9, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Director Purchases $996,748.68 in StockJune 8, 2024 | insidertrades.comInhibrx, Inc. (NASDAQ:INBX) Director Buys $996,748.68 in StockInhibrx, Inc. (NASDAQ:INBX - Get Free Report) Director Jon Faiz Kayyem acquired 57,549 shares of the business's stock in a transaction dated Wednesday, June 5th. The stock was acquired at an average cost of $17.32 per share, with a total value of $996,748.68. Following the completion of the transaction, the director now owns 1,150,410 shares of the company's stock, valued at $19,925,101.20. The transaction was disclosed in a filing with the SEC, which is available at this link.June 7, 2024 | marketbeat.comInhibrx: Continued Advancement Even After INBRX-101 Sale To SanofiJune 7, 2024 | seekingalpha.comInhibrx (NASDAQ:INBX) Trading Up 2%Inhibrx (NASDAQ:INBX) Shares Up 2%June 7, 2024 | marketbeat.comCapital Research Global Investors Sells 509,361 Shares of Inhibrx, Inc. (NASDAQ:INBX)Capital Research Global Investors trimmed its position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 41.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 712,360 shares of the company's stock after selling 509,361 shares during the qJune 7, 2024 | marketbeat.comInhibrx (NASDAQ:INBX) Sees Unusually-High Trading VolumeInhibrx (NASDAQ:INBX) Sees Large Volume IncreaseJune 5, 2024 | marketbeat.comTop 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)June 5, 2024 | benzinga.comInhibrx (NASDAQ:INBX) Sets New 12-Month High at $16.83Inhibrx (NASDAQ:INBX) Sets New 1-Year High at $16.83June 3, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Insider Brendan P. Eckelman Sells 300,000 SharesMay 31, 2024 | insidertrades.comInsider Selling: Inhibrx, Inc. (NASDAQ:INBX) Insider Sells 300,000 Shares of StockInhibrx, Inc. (NASDAQ:INBX - Get Free Report) insider Brendan P. Eckelman sold 300,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.30, for a total value of $10,290,000.00. Following the transaction, the insider now owns 1,735,553 shares in the company, valued at approximately $59,529,467.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.May 30, 2024 | marketbeat.comInhibrx, Inc.: Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiMay 25, 2024 | finanznachrichten.deInhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiMay 24, 2024 | prnewswire.com Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Is the Trump/Musk duo good for shares of TSLA? (Ad)If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla. Discover how to trade Tesla, simply follow this link here. INBX Media Mentions By Week INBX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INBX News Sentiment▼0.230.55▲Average Medical News Sentiment INBX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INBX Articles This Week▼41▲INBX Articles Average Week Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies uniQure News 89bio News Pliant Therapeutics News Relay Therapeutics News Anavex Life Sciences News Keros Therapeutics News Kura Oncology News Immunome News Tyra Biosciences News Erasca News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INBX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
